Welcome to the EACR 2022 Congress. With your participation we will make the 2022 Congress a vibrant and exciting event!
EACR 2022 is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.
The European Association for Cancer Research (EACR) is a non-profit membership association dedicated to the advancement of cancer research. We have been bringing cancer researchers together at our congress and conferences since 1968, and EACR 2022 is our 28th congress.
> Click here to find out more about the EACR and join as a member
We recommend that participants wear a mask or face covering while inside the congress building, but this is not a requirement.
Participants are responsible for checking the requirements in place at the time they travel. Please refer to the official Spanish government page on travel in and out of Spain. You should also check the requirements of the country from which you are travelling.
The EACR and associated Congress organisers will do everything we can to make the event safe. We will comply with any local and international restrictions in place at the time and we reserve the right to introduce checks for proof of vaccination/negative test at any point before the Congress.
Further general information, including terms regarding cancellation not forced by a pandemic, can be found in the Registration Terms & Conditions.
Abstract submission deadline
07 March 2022
Abstract results notification
06 April 2022
Bursary application deadline
07 March 2022
Early registration deadline
20 April 2022
This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.